Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Morepen Laboratories Limited (MOREPENLAB.NS)
Gurugram, IN
Morepen Laboratories Limited is an Indian pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), proprietary and generic pharmaceutical formulations, and a diverse range of home healthcare products. Its API portfolio encompasses compounds utilized in the creation of drugs for conditions such as allergies, asthma, elevated cholesterol, hypertension, and diabetes. The company also supplies an array of point-of-care and medical devices for home use, including diagnostic tools like air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse oximeters, nebulizers, glucometers with accompanying strips, as well as hygiene products such as sanitizers, disinfectant solutions, masks, and gloves. Among its well-known branded products are Burnol, a cream for treating burns; Lemolate, an offering for cough and cold relief; and Fiber-X, a psyllium husk supplement. Furthermore, Morepen produces finished drug formulations covering various therapeutic areas, including gastrointestinal health, antibiotics, vitamins, nutritional support, anti-diabetics, and cardiovascular conditions. Beyond these offerings, the company undertakes contract manufacturing for other businesses and participates in brand sharing agreements. Its comprehensive range of over-the-counter (OTC) products is marketed under the recognizable Dr. Morepen brand. The company's global footprint extends to approximately 75 nations, where its products are exported. Established in 1984, Morepen Laboratories Limited maintains its headquarters in New Delhi, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.06% | -0.83% | +4.18% | -1.33% | -0.71% | +4.92% | -33.56% | +67.67% | -22.08% | +84.15% | +111.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.3% Q1'26: +3.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-21.4% Q1'26: -20.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+0.0% Q1'26: -5.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.6% Q1'26: +5.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.0% ★ Q1'26: +5.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.2% Q1'26: -3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.20× Q1'26: 1.58× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2001 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2021 actual |
|---|---|---|---|---|
| Revenue |
4.36B
est.
|
5.98B
est: 5.78B (+3.4%)
|
7.56B
est: 6.67B (+13.5%)
|
11.75B
est: 10.37B (+13.3%)
|
| EBITDA |
418.36M
est.
|
684.50M
est: 543.47M (+26.0%)
|
711.90M
est: 639.06M (+11.4%)
|
1.30B
est: 999.64M (+30.1%)
|
| EBIT |
332.05M
est.
|
336.41M
est: 431.35M (-22.0%)
|
307.90M
est: 507.21M (-39.3%)
|
998.11M
est: 793.40M (+25.8%)
|
| Net Income |
4.43B
est.
|
295.91M
est: 397.49M (-25.6%)
|
288.49M
est: 536.46M (-46.2%)
|
970.86M
est: 287.34M (+237.9%)
|
| SGA |
435.18M
est.
|
395.81M
est: 565.32M (-30.0%)
|
480.23M
est: 664.75M (-27.8%)
|
618.27M
est: 1.04B (-40.5%)
|
| EPS |
8.25
est.
|
0.66
est: 0.74 (-11.4%)
|
0.64
est: 1.00 (-36.0%)
|
2.16
est: 0.53 (+305.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sushil Suri | Chairman & MD | 33M | male |
| Sanjay Suri | Whole-Time Director | 13M | male |
| Ajay Kumar Sharma | Chief Financial Officer | 10M | male |
| Vipul Kumar Srivastava | Company Secretary & Compliance Officer | 2M | male |
| Sunita Suri | Manager of Administration | — | female |
| Vikas Sharma | Functional Head of Talent Acquisition & HRBP | — | male |
| Vivan Prashar | Functional Head of Operations - API | — | male |
| Amita Sharma | Chief Operating Officer of API | — | female |
| Bhola Prasad | General Manager of Process Engineering & Technology Transfer | — | male |
| Nishant Jayesh Doshi | Vice President Corporate Finance & Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MOREPENLAB.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
